Ebioinformatics has completed its merger with Empatheon and taken a new name, Entigen. The name is indicative of Ebioinformatics’ plan to expand beyond bioinformatics to go after new undisclosed markets using Empatheon’s data integration technology.

Entigen doesn’t mean anything and therefore doesn’t restrict the company to one area like the Ebioinformatics name does, said James Nelson, vice president of product marketing at Entigen.

“And it’s easier to say than Ebioinformatics,” he quipped. The Internet domain name, entigen.com, was also available.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.